Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 5/20 | 0.56 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.51 |
| ▸ | ACLY | P53396 | 3/20 | 0.50 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6862302 | 0.89 | CCR2 (0.59) | CCR2PTGDR2ERBB2HSP90AA1HSP90AB1 | |
| SCHEMBL1138956 | 0.86 | LMNA (0.55) | CCR2PTGDR2ACLYLMNAMEN1 | |
| SCHEMBL6863706 | 0.83 | MRGPRX4 (0.60) | CCR2PTGDR2LMNAMAPTKMT2A | |
| SCHEMBL6861404 | 0.80 | MRGPRX4 (0.56) | CCR2PTGDR2ERBB2HSP90AA1HSP90AB1 | |
| SCHEMBL7622053 | 0.80 | CCR2 (0.69) | CCR2PTGDR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27492180 | 0.78 | CCR2 (0.57) | CCR2PTGDR2ERBB2HSP90AA1HSP90AB1 | |
| SCHEMBL6860435 | 0.76 | CCR2 (0.60) | CCR2ACLYLMNAMEN1MAPT | |
| SCHEMBL6863906 | 0.76 | CYP19A1 (0.54) | SLC40A1LMNAMEN1MAPTKMT2A | |
| SCHEMBL2735697 | 0.76 | RXRA (0.56) | CCR2ACLYLMNAMEN1MAPT | |
| SCHEMBL5300989 | 0.76 | ERBB2 (0.62) | CCR2PTGDR2ERBB2HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1213019-C | Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2005-08-03 | — | — | CN | claimed |
| US-20030060460-A1 | Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity | OHUCHIDA SHUICHI (JP) | 2003-03-27 | — | — | US | claimed |
| CN-1247529-A | Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2000-03-15 | — | — | CN | claimed |
| EP-0947500-A1 | SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | claimed |
| CN-1213019-C | Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2005-08-03 | — | — | CN | disclosed |
| US-6790866-B2 | SUCH AS 4-(2-PHENYLSULFONYLAMINO-5-CHLOROBENZOYLAMINO)BENZOIC ACID FOR USE AS PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; FOR INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, AND/OR FOR INCREASE OF VESICAL CAPACITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20030060460-A1 | Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity | OHUCHIDA SHUICHI (JP) | 2003-03-27 | — | — | US | disclosed |
| US-6448290-B1 | PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, INCREASING VESICAL CAPACITY, CATHARTIC, SUPPRESSION OF GASTRIC ACID SECRETION, ANTIHYPERTENSIVE, DIURETIC AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| EP-0947500-A1 | SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060460-A1 | Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity | CNR1, HCAR1, HCAR2 | CCR2 475/4885PTGDR2 20/4885ERBB2 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.